Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers - Archive ouverte HAL
Article Dans Une Revue Journal of Clinical Microbiology Année : 2022

Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers

Kahina Saker
  • Fonction : Auteur
Vanessa Escuret
Virginie Pitiot
  • Fonction : Auteur
Amélie Massardier-Pilonchéry
  • Fonction : Auteur
Stéphane Paul
Bouchra Mokdad
  • Fonction : Auteur
Muriel Rabilloud
David Goncalves
  • Fonction : Auteur
Nicole Fabien
  • Fonction : Auteur
Nicolas Guibert
  • Fonction : Auteur
Jean-Baptiste Fassier
Antonin Bal
Sophie Trouillet-Assant
Mary-Anne Trabaud

Résumé

With the availability of vaccines, commercial assays detecting anti-severe acute respiratory syndrome coronavirus-2 antibodies (Ab) evolved toward quantitative assays directed to the spike glycoprotein or its receptor binding domain (RBD). The main objective of the present study was to compare the Ab titers obtained with quantitative commercial binding Ab assays, after one dose (convalescent individuals) or two doses (naive individuals) of vaccine, in health care workers (HCW).

Dates et versions

hal-04386977 , version 1 (11-01-2024)

Identifiants

Citer

Kahina Saker, Vanessa Escuret, Virginie Pitiot, Amélie Massardier-Pilonchéry, Stéphane Paul, et al.. Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers. Journal of Clinical Microbiology, 2022, 60 (1), ⟨10.1128/JCM.01746-21⟩. ⟨hal-04386977⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

More